{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:57:18Z","timestamp":1789909038677,"version":"4.0.1"},"reference-count":21,"publisher":"The Endocrine Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: Medullary thyroid carcinoma (MTC) is a well-differentiated neuroendocrine tumor. Distant metastases are the main cause of cancer-related death. Systemic chemotherapy produces only rare tumor responses. Somatostatin analogs and other available modalities are poorly effective to control symptoms.<\/jats:p>\n               <jats:p>Aims: The aim of our study was to evaluate the impact of liver transarterial chemoembolization (TACE) in MTC patients with predominant and progressive liver metastases.<\/jats:p>\n               <jats:p>Patients and Methods: Twelve MTC patients underwent 18 TACE courses (mean, 1.5; range, 1\u20132). Response evaluation criteria in solid tumors were used to evaluate tumor responses. Symptomatic responses were defined by more than a 25% decrease of symptoms intensity.<\/jats:p>\n               <jats:p>Results: Partial radiological tumor response was obtained in five patients (42%) with a median duration of 17 months (mean, 19; range, 15\u201328 months), stabilization in five (42%) with a median duration of 24 months (mean, 24; range, 4\u201339 months), and progression in the remaining two (16%). The five partial tumor responses were observed in the nine patients with less than 30% liver involvement. Clinical response was observed in two of the five patients with diarrhea. Carcinoembryonic antigen did not appear to be a useful marker in this setting. Significant grade 3\u20134 toxicity was observed in one patient who had a major tumor necrosis after TACE.<\/jats:p>\n               <jats:p>Conclusion: TACE should be considered for treating MTC patients with progressive and predominant liver metastasis, and preferably at an early stage during the course of metastatic disease.<\/jats:p>","DOI":"10.1210\/jc.2005-2401","type":"journal-article","created":{"date-parts":[[2006,4,12]],"date-time":"2006-04-12T01:34:11Z","timestamp":1144805651000},"page":"2496-2499","source":"Crossref","is-referenced-by-count":93,"title":["Chemoembolization for Liver Metastases from Medullary Thyroid Carcinoma"],"prefix":"10.1210","volume":"91","author":[{"given":"J.","family":"Fromigue\u0301","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine and Endocrine Tumors (J.F., E.B., S.L., M.S.), 94805 Villejuif Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"De Baere","sequence":"additional","affiliation":[{"name":"Interventional Radiology (T.D.B., C.D.), Institut Gustave Roussy, 94805 Villejuif Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Baudin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Endocrine Tumors (J.F., E.B., S.L., M.S.), 94805 Villejuif Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dromain","sequence":"additional","affiliation":[{"name":"Interventional Radiology (T.D.B., C.D.), Institut Gustave Roussy, 94805 Villejuif Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Leboulleux","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Endocrine Tumors (J.F., E.B., S.L., M.S.), 94805 Villejuif Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schlumberger","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Endocrine Tumors (J.F., E.B., S.L., M.S.), 94805 Villejuif Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071614131060100_R1","first-page":"930","article-title":"Medullary thyroid carcinoma","author":"Ball","year":"2000","journal-title":"In: Braverman LE, Utiger RD, eds. Werner and Ingbar\u2019s the thyroid. 8th ed. Philadelphia: Lippincott Williams and Wilkins;"},{"key":"2020071614131060100_R2","first-page":"1717","article-title":"Multiple endocrine neoplasia","author":"Gagel","year":"2002","journal-title":"In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams textbook of endocrinology. 10th ed. Philadelphia: Saunders;"},{"key":"2020071614131060100_R3","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/(SICI)1097-0142(19960415)77:8<1556::AID-CNCR20>3.0.CO;2-Y","article-title":"Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables","volume":"77","author":"Dottorini","year":"1996","journal-title":"Cancer"},{"key":"2020071614131060100_R4","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/1097-0142(19851101)56:9<2155::AID-CNCR2820560903>3.0.CO;2-E","article-title":"A randomized trial of Doxorubicin versus Doxorubicin plus Cisplatin in patients with advanced thyroid carcinoma","volume":"56","author":"Shimaoka","year":"1985","journal-title":"Cancer"},{"key":"2020071614131060100_R5","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/1097-0142(19881101)62:9<1899::AID-CNCR2820620905>3.0.CO;2-C","article-title":"Metastatic medullary thyroid carcinoma: complete response to combination chemotherapy with dacarbazine and 5 fluorouracil","volume":"62","author":"Petursson","year":"1988","journal-title":"Cancer"},{"key":"2020071614131060100_R6","first-page":"405","article-title":"Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern cancer study group trial","volume":"70","author":"Williams","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"2020071614131060100_R7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0167-8140(87)80004-X","article-title":"Chemotherapy for thyroid cancer","volume":"10","author":"Hoskin","year":"1987","journal-title":"Radiother Oncol"},{"key":"2020071614131060100_R8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/1097-0142(19940115)73:2<432::AID-CNCR2820730231>3.0.CO;2-K","article-title":"Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine and dacarbazine","volume":"73","author":"Wu","year":"1994","journal-title":"Cancer"},{"key":"2020071614131060100_R9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/oxfordjournals.annonc.a058984","article-title":"Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer","volume":"5","author":"Orlandi","year":"1994","journal-title":"Ann Oncol"},{"key":"2020071614131060100_R10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/bjc.1995.73","article-title":"Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d\u2019Etude des Tumeurs a Calcitonine (GETC)","volume":"71","author":"Schlumberger","year":"1995","journal-title":"Br J Cancer"},{"key":"2020071614131060100_R11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1054\/bjoc.2000.1314","article-title":"Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine","volume":"83","author":"Nocera","year":"2000","journal-title":"Br J Cancer"},{"key":"2020071614131060100_R12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2265.1992.tb00955.x","article-title":"Results of long-term continuous subcutaneous octreotide administration of 14 patients with medullary thyroid carcinoma","volume":"36","author":"Modigliani","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071614131060100_R13","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00268-002-6629-5","article-title":"Laparoscopic radiofrequency ablation of neuroendocrine liver metastases","volume":"26","author":"Berber","year":"2002","journal-title":"World J Surg"},{"key":"2020071614131060100_R14","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z","article-title":"Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems","volume":"88","author":"Kebebew","year":"2000","journal-title":"Cancer"},{"key":"2020071614131060100_R15","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1148\/radiology.189.2.7692465","article-title":"Transcatheter chemoembolization of progressive carcinoid liver metastasis","volume":"189","author":"Therasse","year":"1993","journal-title":"Radiology"},{"key":"2020071614131060100_R16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2169\/internalmedicine.38.17","article-title":"Medullary thyroid carcinoma with multiple hepatic metastases: treatment with transcatheter arterial embolization and percutaneous ethanol injection","volume":"38","author":"Isozaki","year":"1999","journal-title":"Intern Med"},{"key":"2020071614131060100_R17","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.surg.2005.09.020","article-title":"Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma","volume":"138","author":"Lorenz","year":"2005","journal-title":"Surgery"},{"key":"2020071614131060100_R18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.7326\/0003-4819-132-7-200004040-00028","article-title":"Chemoembolization of liver metastases from medullary thyroid carcinoma","volume":"132","author":"Machens","year":"2000","journal-title":"Ann Int Med"},{"key":"2020071614131060100_R19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00330-002-1558-0","article-title":"Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors","volume":"13","author":"Roche","year":"2003","journal-title":"Eur J Radiol"},{"key":"2020071614131060100_R20","first-page":"673","article-title":"Liver metastases of digestive endocrine tumours: natural history and response to medical treatment","volume":"8","author":"Skinazi","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2020071614131060100_R21","first-page":"1751","article-title":"Prognostic factors for chemoembolization in liver metastasis from endocrine tumors","volume":"51","author":"Roche","year":"2004","journal-title":"Hepato Gastro Enterol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/91\/7\/2496\/9060516\/jcem2496.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/91\/7\/2496\/9060516\/jcem2496.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T01:40:23Z","timestamp":1594950023000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/91\/7\/2496\/2656258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,1]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,7,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2005-2401","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,1]]}}}